June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Both Endothelin A (ETA) and Endothelin B (ETB) Receptors Are Involved in Neurodegeneration in a Rodent Model of Glaucoma.
Author Affiliations & Notes
  • Raghu R Krishnamoorthy
    North Texas Eye Research Center, UNT Health Science Center, Fort Worth, Texas, United States
  • Nolan Robert McGrady
    North Texas Eye Research Center, UNT Health Science Center, Fort Worth, Texas, United States
  • Shaoqing He
    North Texas Eye Research Center, UNT Health Science Center, Fort Worth, Texas, United States
  • Dorota L Stankowska
    North Texas Eye Research Center, UNT Health Science Center, Fort Worth, Texas, United States
  • Footnotes
    Commercial Relationships   Raghu Krishnamoorthy, None; Nolan McGrady, None; Shaoqing He, None; Dorota Stankowska, None
  • Footnotes
    Support  NIH Grant EY01992 and UNTHSC Intramural Grant
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3409. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Raghu R Krishnamoorthy, Nolan Robert McGrady, Shaoqing He, Dorota L Stankowska; Both Endothelin A (ETA) and Endothelin B (ETB) Receptors Are Involved in Neurodegeneration in a Rodent Model of Glaucoma.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3409.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Ongoing studies in our laboratory have demonstrated a key role of the ETB receptor in causing optic nerve axonal degeneration and retinal ganglion cell (RGC) loss in a rodent model of ocular hypertension. The current study examined the involvement of the ETA receptor in the Morrison’s model of IOP elevation in rats. Additional studies were carried out to determine if the dual ETA/ETB receptor antagonist, macitentan could attenuate neurodegenerative changes following IOP elevation in Brown Norway rats.

Methods : IOP was elevated in one eye of adult male retired breeder Brown Norway rats using the Morrison’s method, while the contralateral eye served as control. Following IOP elevation, rats were maintained for 2 and 4 weeks and sacrificed. Retinal sections were stained with an antibody to the ETA receptor and co-stained with β-tubulin III (a selective marker of the RGC layer) and immunofluorescence analysis was carried out. Primary RGCs were infected with an adeno-associated virus encoding the ETA cDNA following which an immunocytochemical analysis of the ETB receptor and a cell viability assay were carried out. Another set of Brown Norway rats were fed for 1 month with macitentan (10 mg/kg/body weight) during IOP elevation (100 to 120 mm Hg-days). Retinal flat mounts obtained from the rats were assessed for RGC survival by counting surviving RBPMS positive-RGCs.

Results : IOP elevation for 2 weeks produce a modest increase in immunostaining for the ETA receptor in the RGC layer, inner plexiform layer and outer plexiform layer compared to those of wild type rats. Significantly increased immunostaining for the ETA receptor was observed at 4 weeks of IOP elevation in the RGCs and inner plexiform layer. AAV-2 mediated upregulation of the ETA produced an increase expression of the ETB receptor and a decrease in viability of cultured RGCs. Rats fed with macitentan displayed increased RGC survival by 25 to 42% following IOP elevation, compared to untreated rats.

Conclusions : Both ETA and ETB receptors levels are increased following IOP elevation in Brown Norway rats. ETA receptor activation contributes to neurodegeneration possibly by its ability to increase ETB receptor expression. Blocking both ETA and ETB receptors could have neuroprotective effects by enhancing RGC survival without affecting IOP.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×